Center for Biosimilars15h
Real-World Data Confirm Safety of Switching Between Ranibizumab Biosimilars
Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...
pharmaphorum6d
FDA clears Roche's Susvimo implant for eye disease wet AMD
The green light comes on the back of the phase 3 ARCHWAY trial which showed that Susvimo was equivalent to monthly Lucentis injections at maintaining vision in patients over 40 weeks, with 98% of ...
Business Wire1mon
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab ...
Courthouse News Service7y
South Florida Eye Doctor Gets 17 Years for Medicare Fraud
Assistant U.S. Attorney Roger Stefin claimed some of Melgen's patients developed serious eye infections from unnecessary Lucentis injections administered on the basis of bogus macular degeneration ...
Ophthalmology Times12d
PDS implant matches monthly injections in efficacy in DME treatment
In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...
Medscape29d
Finding the Optimal Treatment Plan for Exudative AMD
In this study, 4300 patients received 0.3 or 0.5 mg of ranibizumab every 3 months after the initial series of three monthly injections. After the first 3 injections the mean visual acuity improved ...
Nasdaq1mon
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Basel, 04 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the ...